Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1,651 GBX | +0.70% | +2.51% | +13.85% |
05:25pm | Edwards Lifesciences Corporation: The story continues | |
Apr. 22 | European Equities Close Higher in Monday Trading; EC Probes TikTok Over Possible DSA Violations | MT |
Sales 2024 * | 31.46B 39.13B | Sales 2025 * | 33.33B 41.46B | Capitalization | 66.99B 83.33B |
---|---|---|---|---|---|
Net income 2024 * | 5.63B 7B | Net income 2025 * | 6.37B 7.92B | EV / Sales 2024 * | 2.52 x |
Net Debt 2024 * | 12.16B 15.13B | Net Debt 2025 * | 8.93B 11.1B | EV / Sales 2025 * | 2.28 x |
P/E ratio 2024 * |
11.9
x | P/E ratio 2025 * |
10.6
x | Employees | 70,212 |
Yield 2024 * |
3.71% | Yield 2025 * |
3.97% | Free-Float | 92.58% |
Latest transcript on GSK plc
1 day | +0.84% | ||
1 week | +2.42% | ||
Current month | -3.46% | ||
1 month | -2.66% | ||
3 months | +6.13% | ||
6 months | +12.79% | ||
Current year | +13.74% |
Managers | Title | Age | Since |
---|---|---|---|
Emma Walmsley
CEO | Chief Executive Officer | 55 | 10-04-30 |
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
James Ford
CMP | Compliance Officer | - | 95-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Julie Brown
DFI | Director of Finance/CFO | 62 | 23-04-30 |
Jonathan Symonds
CHM | Chairman | 66 | 19-08-31 |
Urs Rohner
BRD | Director/Board Member | 65 | 14-12-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
3.17% | 11 M€ | +0.83% | - | |
3.15% | 18 M€ | +2.56% | - | |
2.51% | 5 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-04-23 | 1,651 | +0.70% | 3 326 665 |
24-04-22 | 1,640 | +2.53% | 7,020,161 |
24-04-19 | 1,599 | +0.98% | 5,148,977 |
24-04-18 | 1,584 | -0.41% | 5,914,111 |
24-04-17 | 1,590 | -1.27% | 7,387,602 |
Delayed Quote London S.E., April 23, 2024 at 11:15 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+13.74% | 82.63B | |
+27.39% | 659B | |
+27.68% | 557B | |
-4.59% | 359B | |
+16.89% | 322B | |
+9.63% | 297B | |
+6.17% | 215B | |
+5.04% | 210B | |
-6.09% | 200B | |
-8.28% | 149B |
- Stock Market
- Equities
- GSK Stock